Company intelligence / Profile preview

Symbiomix Therapeutics

Newark, New Jersey, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Symbiomix's lead drug candidate SYM-1219 (secnidazole, branded as Solosec) was approved by the FDA on September 15, 2017, for the treatment of bacterial vaginosis in adult women. The drug demonstrated clinically meaningful and highly statistically significant results in Phase 2 and Phase 3 trials[2][9].

Therapeutic areas: Women's Health
Modalities: Small molecules (antibiotics, specifically 5-nitroimidazole)
Industry: Biotech

Drug pipeline

1 asset

secnidazole

Commercial

Indications: Bacterial vaginosis

Beyond the preview

Go deeper on Symbiomix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symbiomix Therapeutics.

Explore the full profile